HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Payback II: Medical Devices Ride the Cash Curve

Executive Summary

The medical device industry has generated returns over the past decade that exceed pharmaceuticals and many other sectors. These returns have been driven by payback on innovation, which the authors from the Boston Consulting Group define as generating cash returns from innovation. Device executives, on the other hand, have generated payback by deftly managing the four S-Factors: start-up costs, speed-to-market, support costs, and scale operations. The challenge for device companies will be maintaining these returns in the face of increased investment in this sector and the threat of health care spending constraints.

You may also be interested in...



Payback: Making Innovation Count in Uncertain Times

Pharmaceutical innovation is not generating payback, the equation for which--and the cash-flow goals--are changing radically. That means that companies must re-think innovation, based on its ability to help companies navigate the four key S-Factors of the cash curve: start-up costs, speed to market, support costs, and scale operations. Some innovations will negotiate this and generate payback; others with apparently equal potential will dawdle in a single phase, consuming cash.

High Science: A Best-Practice Formula for Driving Innovation

The Boston Consulting Group reveals results of a study on how medical technology firms can cultivate and manage their R&D to boost revenue, profits, and even and stock valuations.

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel